NorthWest Healthcare Properties Real Estate Investment Trust

OTCPK:NWHU.F Stock Report

Market Cap: US$928.0m

NorthWest Healthcare Properties Real Estate Investment Trust Valuation

Is NWHU.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NWHU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NWHU.F ($3.91) is trading below our estimate of fair value ($3.93)

Significantly Below Fair Value: NWHU.F is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NWHU.F?

Other financial metrics that can be useful for relative valuation.

NWHU.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.3x
Enterprise Value/EBITDA16.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NWHU.F's PS Ratio compare to its peers?

The above table shows the PS ratio for NWHU.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.8x
DHC Diversified Healthcare Trust
0.6x7.1%US$772.2m
CHTH CNL Healthcare Properties
1.5xn/aUS$521.5m
SILA Sila Realty Trust
6.9x7.0%US$1.3b
UHT Universal Health Realty Income Trust
6.2xn/aUS$600.5m
NWHU.F NorthWest Healthcare Properties Real Estate Investment Trust
2.5x-11.0%US$1.3b

Price-To-Sales vs Peers: NWHU.F is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (3.8x).

Price to Earnings Ratio vs Industry

How does NWHU.F's PE Ratio compare vs other companies in the US Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.5%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.5%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: NWHU.F is good value based on its Price-To-Sales Ratio (2.5x) compared to the US Health Care REITs industry average (5.9x).

Price to Sales Ratio vs Fair Ratio

What is NWHU.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NWHU.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: NWHU.F is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NWHU.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.91
US$4.22
+8.1%
7.3%US$4.81US$3.89n/a6
Aug ’25US$3.66
US$4.19
+14.6%
7.1%US$4.74US$3.83n/a6
Jul ’25US$3.39
US$4.25
+25.1%
6.8%US$4.77US$3.85n/a6
Jun ’25US$3.66
US$4.25
+16.1%
6.8%US$4.77US$3.85n/a6
May ’25US$3.71
US$4.12
+11.0%
9.9%US$4.83US$3.72n/a6
Apr ’25US$3.38
US$4.12
+21.8%
9.9%US$4.83US$3.72n/a6
Mar ’25US$3.00
US$4.12
+37.1%
9.9%US$4.83US$3.72n/a6
Feb ’25US$3.68
US$4.26
+15.9%
8.9%US$4.85US$3.73n/a6
Jan ’25US$3.88
US$4.09
+5.5%
9.5%US$4.75US$3.65n/a7
Dec ’24US$3.37
US$4.09
+21.5%
9.5%US$4.75US$3.65n/a7
Nov ’24US$3.03
US$4.60
+51.8%
10.9%US$5.46US$3.82n/a7
Oct ’24US$3.78
US$5.05
+33.6%
17.7%US$6.63US$4.05n/a7
Sep ’24US$5.01
US$6.17
+23.1%
13.5%US$7.01US$4.80n/a7
Aug ’24US$5.15
US$6.77
+31.5%
17.3%US$8.34US$4.93US$3.667
Jul ’24US$4.72
US$6.99
+48.0%
13.2%US$8.34US$5.31US$3.397
Jun ’24US$5.50
US$7.77
+41.4%
13.2%US$9.63US$6.29US$3.667
May ’24US$5.98
US$7.91
+32.3%
10.8%US$9.60US$6.64US$3.717
Apr ’24US$6.20
US$8.98
+44.9%
8.7%US$9.99US$7.77US$3.387
Mar ’24US$6.89
US$9.28
+34.7%
10.0%US$10.46US$7.84US$3.007
Feb ’24US$7.45
US$9.28
+24.6%
10.0%US$10.46US$7.84US$3.687
Jan ’24US$6.87
US$9.74
+41.8%
8.1%US$10.41US$8.18US$3.887
Dec ’23US$7.55
US$9.74
+29.0%
8.1%US$10.41US$8.18US$3.377
Nov ’23US$7.84
US$10.34
+31.9%
8.5%US$11.39US$8.45US$3.037
Oct ’23US$7.68
US$11.22
+46.1%
6.0%US$12.38US$10.44US$3.787
Sep ’23US$9.35
US$11.22
+20.0%
6.0%US$12.38US$10.44US$5.017
Aug ’23US$10.37
US$11.44
+10.3%
6.4%US$12.41US$10.47US$5.157

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y